Neuroblastoma is the most common solid tumour outside of the brain in children. There is no agreed way of treating these patients and different chemotherapy combinations are used.
Temozolomide, irinotecan and topotecan are commonly used regimens. This study will test whether temozolomide alone or with others is better at treating neuroblastoma. Bevacizumab is a new agent which restricts tumour growth. This trial will test whether treatment is better when bevacizumab is added to chemotherapy.
Irinotecan and Bevacizumab are currently being evaluated. No more patients will receive Irinitotecan or Bevacizumab as part of this trial while the results are being analysed.
Dinutuximab beta is a new agent which uses sugar-fat molecules on tumour cells to allow the body's own immune system to identify the cells and kill them (this is called immunotherapy). This trial is testing whether treatment is better when Dinutuximab beta is added to the other agents (Temozolomide and Topotecan).
Patients will be randomised to receive 1 of 4 combinations of treatment.
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
| Chief Investigator: |
Dr Lucas Moreno |
| Coordinating Sponsor: |
University of Birmingham |
| Funders: |
CRUK (Cancer Research UK), Imagine for Margo & Solving Kid's Cancer |
| Disease Site: |
Brain |
| Trial Type: |
Clinical Trial of an Investigational Medical Product |
| Status: |
Closed to recruitment |
UKCRN Study ID:
|
14229 |
| Open to new sites? |
No |
| Recruitment start date: |
July 2013 |
| Recruitment end date |
Feb 2021 |
| CRCTU Trial Management Team: |
Children's Cancer Trials Team |
| Trial E-mail Address: |
beacon@trials.bham.ac.uk |